Aktuelle News
News Funktionen
Weitere Funktionen
17 Juli 2024
invIOs GmbH
invIOs selects INV501 lead candidate to progress into IND-enabling studies in glioblastoma and melanoma
21 Dezember 2023
invIOs GmbH
invIOs to attend JP Morgan Week in San Francisco in January
9 November 2023
invIOs GmbH
invIOs and Dana-Farber Cancer Institute start collaboration to study novel small molecule INV501 for treatment of glioblastoma
5 September 2023
invIOs GmbH
invIOs starts further clinical trial of APN401, novel cell therapy against solid cancers, and secures major Austrian grant funding
19 Juni 2023
invIOs GmbH
invIOs presents exciting preclinical data showing that immune-activating small molecule INV501 induces strong cytotoxic activity against solid tumors
18 April 2023
invIOs GmbH
invIOs presents promising new clinical data in solid tumors from autologous cell therapy APN401 at AACR Annual Meeting 2023